Hoth Therapeutics, Inc. today announced a development updates for its novel cancer therapeutic, HT-KIT. Hoth’s innovative approach, which employs a chemically-stable antisense oligonucleotide to target the proto-oncogene KIT through by frameshifting KIT mRNA transcripts, has potential as a KIT-targeted therapeutic alone, or in combination with agents that target KIT signaling, in the treatment of KIT-associated…
eTurboNews amanqaku ngababhalisi kuphela. Umrhumo ngu fREE.
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
INTO ONOKUYITHATHA KWELI NQAKU:
- Hoth’s innovative approach, which employs a chemically-stable antisense oligonucleotide to target the proto-oncogene KIT through by frameshifting KIT mRNA transcripts, has potential as a KIT-targeted therapeutic alone, or in combination with agents that target KIT signaling, in the treatment of KIT-associated….
- today announced a development updates for its novel cancer therapeutic, HT-KIT.
- eTurboNews amanqaku ngababhalisi kuphela.
